Ginkgo Bioworks Holdings (DNA) Net Cash Flow Growth (1y) (2021 - 2026)
Ginkgo Bioworks Holdings (DNA) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 53.46% |
| 10 | Ginkgo Bioworks Holdings | 442.44 Mn | 298.57 Mn | 16.38 Mn | 90.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.35% |
| Dec 31, 2025 | 199.71% |
| Sep 30, 2025 | 17.24% |
| Jun 30, 2025 | -1.40% |
| Mar 31, 2025 | -136.41% |
| Dec 31, 2024 | 47.00% |
| Sep 30, 2024 | -47.79% |
| Jun 30, 2024 | -29.39% |
| Mar 31, 2024 | 7.82% |
| Dec 31, 2023 | -557.67% |
| Sep 30, 2023 | -2.67% |
| Jun 30, 2023 | 25.04% |
| Mar 31, 2023 | -94.28% |
| Dec 31, 2022 | 113.33% |
| Sep 30, 2022 | -104.98% |
| Jun 30, 2022 | -88.49% |
| Mar 31, 2022 | 20.30% |
| Dec 31, 2021 | -95.07% |